Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice

Vaccine

Volumn 31, Issue 8, 2013, Pages 1210-1216

  Asadi Karam, Mohammad Reza ^a   Oloomi, Mana ^a   Mahdavi, Mehdi ^a   Habibi, Mehri ^a   Bouzari, Saeid ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Adjuvant; FimH; Flagellin; Montanide; Urinary tract infection; Vaccine

Indexed keywords

FLAGELLIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MONTANIDE ISA 206; MONTANIDE ISA 51; RECOMBINANT FIMH PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TH1 CELL; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VACCINATION;

ADHESINS, ESCHERICHIA COLI; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; FIMBRIAE PROTEINS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES; URINARY BLADDER; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI; VACCINATION; VACCINES, SYNTHETIC;

EID: 84873079109     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.059     Document Type: Article

References (45)

1. Ragnarsdottir B., Fischer H., Godaly G., Gronberg-Hernandez J., Gustafsson M., Karpman D., et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008, 38(October (Suppl. 2)):12-20.
2. Bien J., Sokolova O., Bozko P. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol 2012, 2012:681473.
3. Dhakal B.K., Kulesus R.R., Mulvey M.A. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 2008, 38(October (Suppl. 2)):2-11.
4. Haugen B.J., Pellett S., Redford P., Hamilton H.L., Roesch P.L., Welch R.A. In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA. Infect Immun 2007, 75(January (1)):278-289.
5. Lane M.C., Lockatell V., Monterosso G., Lamphier D., Weinert J., Hebel J.R., et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun 2005, 73(November (11)):7644-7656.
6. Anderson G.G., Martin S.M., Hultgren S.J. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microbes Infect 2004, 6(October (12)):1094-1101.
7. Mulvey M.A. Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 2002, 4(May (5)):257-271.
8. Lane M.C., Simms A.N., Mobley H.L. Complex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coli. J Bacteriol 2007, 189(August (15)):5523-5533.
9. Welch R.A., Burland V., Plunkett G., Redford P., Roesch P., Rasko D., et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A 2002, 99(December (26)):17020-17024.
10. Nesta B., Spraggon G., Alteri C., Moriel D.G., Rosini R., Veggi D., et al. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 2012, 3.(2).
11. Langermann S., Palaszynski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997, 276(April (5312)):607-611.
12. Hagan E.C., Mobley H.L. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect Immun 2007, 75(August (8)):3941-3949.
13. Langermann S., Ballou W.R. Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 2001, 183(March (Suppl. 1)):S84-S86.
14. Martinez J.J., Mulvey M.A., Schilling J.D., Pinkner J.S., Hultgren S.J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000, 19(June (12)):2803-2812.
15. Wright K.J., Seed P.C., Hultgren S.J. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 2007, 9(September (9)):2230-2241.
16. Thankavel K., Madison B., Ikeda T., Malaviya R., Shah A.H., Arumugam P.M., et al. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. J Clin Invest 1997, 100(September (5)):1123-1136.
17. Russo T.A., McFadden C.D., Carlino-MacDonald U.B., Beanan J.M., Olson R., Wilding G.E. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun 2003, 71(December (12)):7164-7169.
18. Billips B.K., Yaggie R.E., Cashy J.P., Schaeffer A.J., Klumpp D.J. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis 2009, 200(July (2)):263-272.
19. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(January (4)):763-775.
20. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006, 74(February (2)):1113-1120.
21. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004, 72(May (5)):2810-2816.
22. Vandewalle A. Toll-like receptors and renal bacterial infections. Chang Gung Med J 2008, 31(November-December (6)):525-537.
23. Honko A.N., Mizel S.B. Effects of flagellin on innate and adaptive immunity. Immunol Res 2005, 33(1):83-101.
24. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(December (12)):1247-1253.
25. Skountzou I., Martin Mdel P., Wang B., Ye L., Koutsonanos D., Weldon W., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(May (24)):4103-4112.
26. Bargieri D.Y., Rosa D.S., Braga C.J., Carvalho B.O., Costa F.T., Espindola N.M., et al. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008, 26(November (48)):6132-6142.
27. Mizel S.B., Graff A.H., Sriranganathan N., Ervin S., Lees C.J., Lively M.O., et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009, 16(January (1)):21-28.
28. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(January (1)):694-702.
29. Ben-Yedidia T., Arnon R. Epitope-based vaccine against influenza. Expert Rev Vaccines 2007, 6(December (6)):939-948.
30. McDonald W.F., Huleatt J.W., Foellmer H.G., Hewitt D., Tang J., Desai P., et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 2007, 195(June (11)):1607-1617.
31. Karam M.A., Oloomi M., Habibi M., Bouzari S. Cloning and expression of the fusion protein FimH/FliC from Uropathogenic Escherichia coli (UPEC) isolate from Iran. Iran J Microbiol 2012, 4(2):1-7.
32. Reichelt P., Schwarz C., Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 2006, 46(April (2)):483-488.
33. Takahashi K., Sugi Y., Hosono A., Kaminogawa S. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J Immunol 2009, 183(November (10)):6522-6529.
34. Tallant T., Deb A., Kar N., Lupica J., de Veer M.J., DiDonato J.A. Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMC Microbiol 2004, 4(August):33.
35. Tebianian M., Hoseini A.Z., Ebrahimi S.M., Memarnejadian A., Mokarram A.R., Mahdavi M., et al. Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70. Biologicals 2011, 39(May (3)):143-148.
36. Wieser A., Romann E., Magistro G., Hoffmann C., Norenberg D., Weinert K., et al. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 2010, 78(August (8)):3432-3442.
37. Nguyen C.T., Kim S.Y., Kim M.S., Lee S.E., Rhee J.H. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011, 29(August (34)):5731-5739.
38. Pino O., Martin M., Michalek S.M. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect Immun 2005, 73(October (10)):6763-6770.
39. McSorley S.J., Ehst B.D., Yu Y., Gewirtz A.T. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 2002, 169(October (7)):3914-3919.
40. Halassy B., Vdovic V., Habjanec L., Balija M.L., Gebauer B., Sabioncello A., et al. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits. Vaccine 2007, 25(April (17)):3475-3481.
41. Habjanec L., Halassy B., Tomasic J. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. Int Immunopharmacol 2008, 8(May (5)):717-724.
42. Cox S.J., Aggarwal N., Statham R.J., Barnett P.V. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 2003, 21(March (13-14)):1336-1347.
43. Sivick K.E., Schaller M.A., Smith S.N., Mobley H.L. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol 2010, 184(February (4)):2065-2075.
44. Thumbikat P., Berry R.E., Zhou G., Billips B.K., Yaggie R.E., Zaichuk T., et al. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog 2009, 5(May (5)):e1000415.
45. Jones-Carson J., Balish E., Uehling D.T. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J Urol 1999, 161(January (1)):338-341.